IDH1 and central nervous system cancer: Preliminary results of the first-in-human, multicenter, phase I study (NCT03030066) investigating the safety of DS-1001b in 45 patients with a diagnosis of recurrent/progressive IDH1-mut glioma were presented at the ASCO annual meeting 2019 (Table 2).